We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Solventum (SOLV) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Solventum (SOLV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.45 per share, reflecting a decline of 7.1% compared to the same period last year. Revenues are forecasted to be $2.12 billion, representing a year-over-year increase of 1.9%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Solventum metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Net Sales- MedSurg' to reach $1.18 billion. The estimate suggests a change of +1.6% year over year.
Analysts predict that the 'Net Sales- Purification and Filtration' will reach $242.52 million. The estimate indicates a year-over-year change of +1.9%.
The consensus estimate for 'Net Sales- Health Information Systems' stands at $334.42 million. The estimate points to a change of +2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- Dental Solutions' should arrive at $332.90 million. The estimate suggests a change of +0.6% year over year.
Over the past month, shares of Solventum have returned -4% versus the Zacks S&P 500 composite's +1% change. Currently, SOLV carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of Solventum (SOLV) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
In its upcoming report, Solventum (SOLV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.45 per share, reflecting a decline of 7.1% compared to the same period last year. Revenues are forecasted to be $2.12 billion, representing a year-over-year increase of 1.9%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Solventum metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Net Sales- MedSurg' to reach $1.18 billion. The estimate suggests a change of +1.6% year over year.
Analysts predict that the 'Net Sales- Purification and Filtration' will reach $242.52 million. The estimate indicates a year-over-year change of +1.9%.
The consensus estimate for 'Net Sales- Health Information Systems' stands at $334.42 million. The estimate points to a change of +2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- Dental Solutions' should arrive at $332.90 million. The estimate suggests a change of +0.6% year over year.
View all Key Company Metrics for Solventum here>>>Over the past month, shares of Solventum have returned -4% versus the Zacks S&P 500 composite's +1% change. Currently, SOLV carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .